[1] European Association for the Study of the Liver. EASL clinical practice guidelines: Drug-induced liver injury. J Hepatol, 2019,70(6):1222-1261.
[2] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南.临床肝胆病杂志, 2015,31(11):1752-1769.
[3] Hu PF, Xie WF. Corticosteroid therapy in drug-induced liver injury: pros and cons. J Dig Dis, 2019,20(3):122-126.
[4] Hu PF, Wang PQ, Chen H, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis, 2016,17(9):618-627.
[5] Chalasani N, Fontana R, Davern T, et al. Characteristics of patients with idiosyncratic drug induced liver injury (DILI) who receive systemic corticosteroids. Am J Gastroenterol, 2008,103:S144-145.
[6] Stephens C, Robles-Diaz M, Medina-Caliz I, et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI registry. J Hepatol, 2021,75(1):86-97.
[7] Niu H, Ma J, Medina-Caliz I, et al. Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis. Aliment Pharmacol Ther, 2022,00:1-11.
[8] Wang CY, Deng Y, Li P, et al. Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study. Hepatology, 2022,75(6):1373-1385.
[9] Wang JB, Huang A, Wang Y, et al. Corticosteroid plus glycyrrhizin therapy for chronic drug-or herb-induced liver injury achieves biochemical and histological improvements: a randomized open-label trial. Aliment Pharmacol Ther, 2022,55: 1297-1310.
[10] Teschke R, Eickhoff A. Editorial: chronic DILI and HILI -corticosteroid plus glycyrrhizin as standard therapy?. Aliment Pharmacol Ther, 2022,56(1):166-167.
[11] Wang JB, Huang A, Wang Y, et al. Editorial: chronic DILI and HILI-corticosteroid plus glycyrrhizin as standard therapy?. Authors' reply. Aliment Pharmacol Ther, 2022,56(1):168-169.
[12] Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol, 2021,39(36):4073-4126.
[13] 施国明,黄晓勇,任正刚,等.肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版).中华消化外科杂志,2021,20(12):1241-1258.
[14] Liu Z, Zhu Y, Xie H, et al. Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Front Pharmacol, 2022,13:1077468.
[15] Bj?rnsson ES, Vucic V, Stirnimann G, et al. Role of corticosteroids in drug-induced liver injury. a systematic review. Front Pharmacol, 2022,13:820724. |
